Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 9/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291508 | 0.94 | CSNK2A1 (0.38) | CSNK2A1BRD4BRD9MAP3K5BRD7 | |
| SCHEMBL22291460 | 0.78 | MAP3K5 (0.39) | BRD4MAP3K5EGFR | |
| SCHEMBL15548916 | 0.78 | MAP3K5 (0.35) | CSNK2A1MAP3K5EGFR | |
| SCHEMBL21224811 | 0.75 | BRD4 (0.37) | BRD4BRD9BRD7 | |
| SCHEMBL23783123 | 0.73 | RAB9A (0.40) | BRD4BRD9BRD7 | |
| SCHEMBL30207466 | 0.73 | RAB9A (0.40) | BRD4BRD9BRD7 | |
| SCHEMBL24569353 | 0.73 | L3MBTL1 (0.48) | BRD9 | |
| SCHEMBL22291627 | 0.72 | BRD9 (0.38) | BRD4BRD9MAP3K5BRD7EGFR | |
| SCHEMBL22291649 | 0.72 | BRD9 (0.38) | BRD4BRD9MAP3K5BRD7EGFR | |
| SCHEMBL22291574 | 0.71 | MAP3K5 (0.34) | BRD4BRD9MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| CN-113874016-A | Compound and use thereof | 福宏治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CSNK2A1 1585/4885BRD4 42/4885BRD9 259/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CSNK2A1 1585/4885BRD4 42/4885BRD9 259/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | CSNK2A1 149/4885BRD4 15/4885BRD9 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.